87results about How to "Small fluctuations in blood concentration" patented technology

The invention discloses high-glycosylation human growth hormone fusion protein. The human growth hormone fusion protein provided by the invention is characterized in that human growth hormone (hGH), flexible peptide joint (L), at least one human chorionic gonadotropin beta-subunit carboxyl terminated rigid peptide (CTP) and human immunoglobulin Fc fragments are sequentially contained from the end N to the end C. The invention also discloses a method for effectively preparing the fusion protein. The built fusion protein has more excellent in vivo medicine effect than recombination hGH; the in vivo circulation half-life period is prolonged; the medication administration frequency is greatly reduced; in addition, the bioavailability is improved; meanwhile, the production process is more simple and efficient.

The present invention relates to an olaparib oral controlled-release and sustained-release pharmaceutical composition, which contains dissolution form improved olaparib and a matrix polymer for release rate adjustment. According to the present invention, the in vivo absorption behavior, the blood drug level and the PARP enzyme inhibition level of the pharmaceutical composition can be controlled, the pharmaceutical composition has the improved olaparib loading and / or oral absorption and / or bioavailability and / or blood drug concentration control and / or enzyme inhibition level control, and can beused as the sole preparation or can be combined with other treatment methods in the treatment of cancer.

The invention discloses a niraparib oral controlled-release and sustained-release pharmaceutical composition and uses thereof. According to the presebt invention, by regulating the niraparib release behavior, the in vivo absorption rate and the absorption time of niraparib can be controlled, and the blood concentration and the blood concentration fluctuation range of niraparib in vivo can be regulated, such that the in vivo PARP enzyme inhibition activity of niraparib can be efficiently and permanently provided so as to provide the antitumor treatment effect in the high-efficiency and low-toxicity manner; a purpose of the present invention is to control the in vivo blood concentration and the efficacy providing of niraparib through the controlled-release and sustained-release preparation so as to improve the treatment effect of the drug and reduce the toxic-side effect of the drug; and the efficient and long-acting PARP enzyme activity inhibition pharmaceutical composition is providedfor patients, wherein the antitumor effect is improved, the acting time is long, the compliance is good, and the toxic-side effect is low.

The invention relates to a preparation method of a pharmaceutical composition for treating type II diabetes, belonging to the medical preparations containing organic ingredients, particularly relating to a preparation method of a pharmaceutical composition of metformin hydrochloride and glimepiride. In the preparation method, the metformin hydrochloride and the glimepiride are taken as active ingredients of the pharmaceutical composition, the metformin hydrochloride is firstly prepared into pill cores by adopting an osmotic pump technology and then the metformin hydrochloride pill cores are coated with the glimepiride by using a coating technology. The preparation method comprises the following steps: 1), preparing the metformin hydrochloride and pharmaceutically acceptable auxiliary materials into pills which are coated with semipermeable membrane layers, punching by laser and producing the pill cores; and 2), preparing the glimepiride and the pharmaceutically acceptable auxiliary materials into a coating liquid dissolved in stomach and carrying out coating on the pill cores in step 1. The invention provides the preparation method of the pharmaceutical composition for treating the type II diabetes, wherein the pharmaceutical composition steady and slowly releases drugs, has reduced administration times, good patients compliance, small side effect and small tablet volume, is less influenced by pH values of different segments of a gastrointestinal tract, and is convenient for administration for the patients.